(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt - 2In the background: Visiting Notable Film Areas All over the Planet
- 3What to watch for in weight loss drugs in 2026
- 4High Court freezes government move to shutter Army Radio pending ruling
- 5Instructions to Construct an Organization While Chasing after a Web-based Degree
- How grandchildren are stepping up to fill the caregiver gap
- Language Learning Applications for Voyagers
- First stop, the Moon. Next stop, Mars? Why Nasa's mission matters
- Figure out How to Augment Eco-friendliness in Your Volvo XC40
- Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- Instructions to Really Oversee Unsold SUVs in the Auto Business
- The Difficulties of Getting a Green Card in the US
- 10 Moving Design Frill for Summer 2023
- Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion
